A股異動丨康恩貝漲停 促進中醫藥傳承創新發展的意見發佈
格隆匯10月31日丨康恩貝(600572.SH)漲停,報7.18元,成交8.3億元,總市值191.5億元。《中共中央國務院關於促進中醫藥傳承創新發展的意見》近日發佈。內容主要包括:健全中醫藥服務體系;發揮中醫藥在維護和促進人民健康中的獨特作用;大力推動中藥質量提升和產業高質量發展;加強中醫藥人才隊伍建設;促進中醫藥傳承與開放創新發展;改革完善中醫藥管理體制機制。康恩貝集團已躋身中國中藥產業前列,引領着中國植物藥產業的發展。其中,世界上首個以油菜花粉為原料治療前列腺增生的藥物“前列康”自1985年上市後,經過20餘年的發展,已成為國內治療前列腺疾病第一植物藥品牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.